Prostatype Genomics AB (OSTO:PROGEN) Pretax Margin %: -5,914.66% (As of Dec. 2025)


OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
25 GF Score
Price kr0.43
GF Value kr0.11
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Pretax Margin %?

Prostatype Genomics AB OSTO:PROGEN -4.23% 25 Pretax Margin % is -5,914.66% as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks worse than 97.03% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Prostatype Genomics AB's Pre-Tax Income for the six months ended in Dec. 2025 was kr-20.58 Mil. Prostatype Genomics AB's Revenue for the six months ended in Dec. 2025 was kr0.35 Mil. Therefore, Prostatype Genomics AB's pretax margin for the quarter that ended in Dec. 2025 was -5,914.66%.

The historical rank and industry rank for Prostatype Genomics AB's Pretax Margin % or its related term are showing as below:

OSTO:PROGEN' s Pretax Margin % Range Over the Past 10 Years
Min: -156300   Med: -7492.09   Max: -3055.68
Current: -7492.09


OSTO:PROGEN's Pretax Margin % is ranked worse than
97.03% of 202 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565 vs OSTO:PROGEN: -7492.09

Prostatype Genomics AB  (OSTO:PROGEN) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Prostatype Genomics AB Pretax Margin % Related Terms


Prostatype Genomics AB Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Pretax Margin % Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial -156,300.00 -4,258.71 -3,055.68 -20,628.64 -7,492.09

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,299.23 -17,100.87 -25,459.52 -9,723.58 -5,914.66

OSTO:PROGEN vs TMO, DHR, IDXX: Pretax Margin % Comparison

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB Pretax Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Pretax Margin % falls into.


OSTO:PROGEN
25GF Score
Prostatype Genomics AB OSTO:PROGEN
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Prostatype Genomics AB's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-44.503/0.594
=-7,492.09 %

Prostatype Genomics AB's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-20.583/0.348
=-5,914.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -5,914.66% mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Pretax Margin % of -5,914.66% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Prostatype Genomics AB and its competitors. According to the industry distribution chart, Prostatype Genomics AB ranks #196 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 97%.
Is Prostatype Genomics AB's Pretax Margin % too high?
Prostatype Genomics AB's current Pretax Margin % is -5,914.66%. Based on the distribution chart, Prostatype Genomics AB ranks #196 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #196 out of 202 companies for Pretax Margin %. This places Prostatype Genomics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Pretax Margin % is -5,914.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.43 — trading 290.9% above its estimated fair value. The current Pretax Margin % is -5,914.66%. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Pretax Margin % is -5,914.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.43 is trading 290.9% above its estimated GF Value™ of kr0.11. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • Pretax Margin %: -5,914.66%
  • GF Value™: kr0.11 vs. price of kr0.43 (290.9% above fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score

Get the complete analysis for OSTO:PROGEN

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.43
Price
kr0.11
GF Value